As soon as the cystic fibrosis (CF) gene was cloned in 1989 an active debate began about the merits of population screening for heterozygotes. Substantial screening programmes for three other recessive genetic disorders, Tay-Sachs disease,'~thalassaernia," and sickle cell anaemia,' had already been carried out with varying degrees of success. Although none of these is common in populations of highest CF frequency, there was a feeling that adequate lessons had been learnt about how to apply genetic screening to comprehensive target groups.
There was, however, one major difference. In Tay-Sachs disease,~thalassaemia, and sickle cell anaemia the test for heterozygosity is based on analysis of the products of mutant genes. The problem of molecular heterogeneity could thus be avoided. Cystic fibrosis was quite different. From the first reports of the gene cloning two factors were apparent. There was no chance of carrying out tests of CF heterozygosity through measurement of the gene product, the cystic fibrosis transmembrane conductance regulator, because it was not expressed in accessible tissues. Furthermore, the CF gene was very heterogeneous. ' Over 350 mutant CF alleles have now been reported. In the British population the~F508 allele represents about 75% of the total, while the G551D and G542X alleles contribute another 10%. Most of the other mutations are found at below 1%.5 For most centres contemplating population screening, the realistic expectation was that only 85 % of CF alleles would be detected. Inevitably this creates a problem for couples where one partner was found to carry a mutant allele while the other did not. Such "positive-negative" couples would have a residual risk of producing a child with CF of about 1 in 640.
The problem of the positive-negative couple loomed large in the minds of many commentators."? It was suggested that screening should be delayed until at least 96% of alleles were detectable as the residual risk in positivenegative couples of producing a child with CF would then be no greater than the population risk of 1 in 2500. 8 9 Others were not persuaded that this was a legitimate view and pointed to the success of other prenatal screening programmes at substantially lower detection rates. 10 11 An 85% detection rate would disclose over 70% of affected fetuses (85% x 85%), and would thus contribute substantially to the reduction in birth prevalence of a serious and lifeshortening disease."
Target groups
Four potential target groups for heterozygote screening have been suggested:
• Neonates • High school children • Young adults • Pregnant women.
There has been little enthusiasm for neonatal testing, despite the ease with which this might be grafted onto existing screening programmes that use Guthrie cards. Problems of consent might prove vexatious, and the information gathered would have no practical use until the screened person reached reproductive age. It was noted that some of the new programmes of neonatal testing for CF homozygosity were inadvertently detecting CF heterozygotes." The problem of how to deal with these had yet to be addressed.
There are several theoretical advantages in screening children of high school age. Scriver et al have shown that this worked well for Tay-Sachs and~thalassaemia screening in Montreal schools. 1415 The whole concept of genetic risk could be tied into an imaginative programme of biology teaching. Nonetheless, in the United Kingdom there are unresolved problems of parental consent for those under 16. There is also some information suggesting that knowledge of carrier status may not be retained by school children until the age at which it is needed."
Largely for these reasons the major pilot programmes of CF heterozygosity testing which have been reported have been concerned with young adults and with pregnant women.
Heterozygosity screening in primary care In many respects screening through primary health care services, such as general practitioner surgeries or family planning clinics, and at or near reproductive age, is the ideal programme. It is most comparable with the principle of individual autonomy. An identified carrier can, if he or she wishes, ignore the information, change marriage partners, have artificial insemination by a screened donor, forego having a child, or choose to have a pregnancy monitored by prenatal diagnosis. In practice, however, experience from the Tay-Sachs' and~thalassaernia" screening programmes has shown that the only option seriously considered by carriers identified in this way is prenatal diagnosis and selective termination of pregnancy. Thus the main advantage of screening in primary care is that it allows individuals the opportunity for considered reflection before they make the choice as to how to handle their carrier status.
Two pilot trials of carrier screening through primary health care services have shown that the method of approach to potential partici-pants is critical in determining the take up rate.
Watson et at found that when the offer of screening was made opportunistically and in person by a member of the research team, between 66 and 87% of those approached agreed to be tested." In contrast, when screening was presented by an invitation letter the take up rate was only 10%. Bekker et at reached similar conclusions. 17 When there was active opportunistic contact and immediate testing the acceptance rate was 70%; for other methods of presentation participation was meagre. Bekker et at concluded that the most important variable determining participation rates in screening was the personal approach by a professional and the offer of immediate carrier testing."
Pregnancy screening in antenatal clinics
Two types of CF screening in antenatal clinics have been proposed: "two-step"!" and "couple" . 19 Although they are not mutually exclusive, the two-step model tests women first and then moves on to the male partner only when the woman is shown to be a carrier. There is a delay between the phases of testing and it is possible in principle for a woman to be tested while her partner refuses to participate. In contrast, in the couple model both partners must agree to participate before testing begins.
In most cases only one of the parents need be tested because a negative result means that the couple are not at high risk.
A large trial of two-step screening in the antenatal clinics of a major Edinburgh maternity hospital has recently been completed." The offer of testing was made by a specially designed leafier" sent with a booking clinic appointment at an early stage of pregnancy.
Women agreeing to participate were tested for six mutant CF alleles, representing 85% of CF chromosomes. If a woman was found to be positive her partner was also tested. No further action was taken when a woman was negative, or if she were positive and her partner negative. An offer of prenatal diagnosis was made to couples with a 1 in 4 risk of bearing an affected child. Table 1 presents the full results of this trial. The take up rate of screening was 83% for eligible women and 71 % when set against all women to whom the offer was made. All but 131 one of the 190 carriers identified were able to persuade their male partners to undergo testing. All seven couples where both partners were a CF heterozygote elected to undergo prenatal diagnosis. One couple had two successive pregnancies with an affected fetus, and in each case the pregnancy was terminated and the diagnosis confirmed. Similar results have been reported by Schwartz et at in a Danish population where 80% of 3000 women accepted the offer of screening." Two-step screening of the type outlined in table 1 does generate some anxiety among women found to be positive for CF alleles while they await their partner's test result. A way around this problem was suggested by Wald. 19 He proposed that the screening unit should be the couple; positive couples were those where each partner carried a CF allele, while negative couples were those where only one partner was tested or where both partners were tested and only one found to be a carrier. Whereas two-step screening generates two types of screen negative couple, a large group with a low risk and a smaller group with an intermediate risk, couple screening generates a single class of screen negative couple, whose composite risk is satisfactorily low. Because in most cases it is only necessary to test one sample from a couple, the number of assays performed is no different from that in two-step screening.
An extended trial of couple screening in the antenatal clinics of two Edinburgh maternity hospitals shows that the take up rates are little different from those encountered in two-step screening (table 2).23 Some 76% of eligible couples participated, while the figure for the overall group was 69%. There was little sign that participants wished to know their individual carrier status. The data were freely available either in the obstetric notes or on application to the screening coordinator; only 1·5% of participants sought this information. Couple screening is a remarkably easy and trouble free mode of delivery of carrier testing, and has become the method of choice in Edinburgh maternity hospitals. Wald et at have also reported a satisfactory 68% take up of couple screening." 
Pregnancy screening in primary care
One of the problems of screening in antenatal clinics is that the time of first booking may be too late to allow necessary action to be taken in the first trimester of pregnancy. Harris et at have suggested that this problem can be circumvented if general practitioners offer heterozygote testing to women at the time of a positive pregnancy test." A pilot trial claimed that this was a viable option, though no data on take up rates were provided. It was pointed out, however, that there are 33839 general practitioners in the United Kingdom, and the chance of persuading a reasonable number of these to participate in CF screening seems improbable. At best, such screening must be seen as a useful adjunct to more generally applicable programmes.
Opportunistic testing
It has been argued that if a woman undergoes an invasive and potentially hazardous investigation such as amniocentesis or chorionic villus biopsy she is entitled to obtain maximum information from the process. Schwartz et al offered CF heterozygote testing to 3545 women about to undergo first trimester prenatal diagnosis, usually because of advanced maternal age, and recorded an acceptance rate of 98%. 22 Instead of screening mothers and fathers for heterozygosity, Brambati et al chose to test the fetal sample in 780 pregnancies undergoing first and early second trimester transabdominal chorionic villus sampling." The acceptance rate was 98%. One affected fetus was detected as well as 12 who were apparently heterozygous for the~F508 allele. In two of the latter cases, however, termination of pregnancy was requested. A worrying aspect of this type of opportunistic testing is that women at a heightened state of anxiety may not be able to accept CF heterozygosity in their fetus as normal."
Cascade testing
Most genetic centres now offer testing for CF heterozygosity to first and second degree relatives of affected subjects. In general such programmes are reactive, and respond to an individual's request. Super et al suggest a more proactive approach, taking screening out into the population by focusing on the relatives of index cases." They argue that in this way the ratio of carriers detected to people tested will be higher, that only one mutant allele need be screened for, and that less anxiety would be generated among the screened population.
There is no doubt that cascade testing could be a very effective way of identifying large numbers of carriers and carrier couples with a great deal less effort than in any standard population screening. It is not, however screening in the conventional sense of the word. Access to the test is not equal, and the probability of being offered screening is a function of relatedness to the index case. Most people have difficulty remembering the names of first cousins once removed or second cousins. Cascade testing would need to reach to the fourth cousin level to attempt the same cover as population screening. Even at that Pilot programmes of CF testing now make it possible to ascertain whether screening has had harmful consequences. In a programme carried out in primary care Watson et al found that 81 % of carriers were glad that they had been tested, and although varying degrees of anxiety were found to be initially associated with a positive result, most of this was allayed by genetic counselling with no adverse long term psychological consequences." At six months after the test 55% of carriers reported that they were not worried. A large proportion of partners (87%) of carriers were also tested. In this group it was difficult to ascertain attitudes to future reproduction; however, significantly fewer individuals in "at risk" partnerships felt that they would refrain from having children after testing and counselling than before. This may be the consequence of an increased awareness of the availability of prenatal diagnosis or simply that carriers now give more concerted thought to potential risks in future pregnancies.
Carrier testing during pregnancy, particularly using the two-step mode of delivery, might be expected to generate some anxiety. Mennie et al showed that this was of comparatively short duration with a reversion to the normal state by the time that the partner was tested." [32] [33] [34] In any event, couple screening would avoid most of this anxiety without loss of detection. 
Questions to Professor Brock Public health delegate, Wessex
Isn't it possible that the difference between the take up rate between those who are given time to consider the test and those who are given tests straight away is because those who have thought through the implications fully don't actually want the test and those who take the test straight away are doing so under some pressure?
The tests you refer to are carried out in prim-* * * ary care and as I have not been involved in them I can't really comment. I should make it clear, however, that in the antenatal clinics we are running, an invitation to take part in the tests is sent out with the booking letter before the appointment. Thus patients have three to four weeks to consider the implications, discuss the test with their partner and friends, and decide whether or not they will participate. For our trial, therefore, everybody has time to reflect on the screening test.
Professor N Wald, editor, Journal of Medical Screening
Firstly, a plea -could the Aberdeen group abandon the term non-disclosure screening? It suggests that you are deliberately concealing information, though that isn't the case. In fact you are giving the information that is necessary for a couple to make an informed choice in a way that will maximise the potential benefit to them and minimise the anxiety. Secondly, what proportion of partners came with the women to the first booking visit after they knew there was going to be couple screening? In Oxford we found it was 50%.
It was about 20% in one hospital and maybe slightly higher in the other. The slight bias is for a higher percentage in groups of higher social class.
Dr H J Harris, general practitioner
Antenatal screening carried out in general practice has a number of advantages. Firstly, patients book early -at about eight weeks ofgestation -so there is plenty of time to consider the options. Secondly, we know our patients well and the environment is familiar and non-threatening. Thirdly, we hold lifetime records of our patients, disease registers, and more recently, family history registers.
Cystic fibrosis may act as a model for other genetic screening opportunities in the future and general practitioners are well placed to provide this service provided that they are supported by back up and education.
I accept entirely what you say. However, as there are around 33 000 general practitioners in the country it may be difficult to persuade them all to screen for cystic fibrosis and to take part in subsequent screening programmes -for fragile X, for example. General practitioners vary enormously in their enthusiasm and this would raise the problem of equity, without which a screening programme is seriously deficient.
Thus there may be a problem with general practitioner based screening and the model I would prefer is antenatal clinic based screening with general practitioner supplementation.
Dr S Sebugwawo, senior registrar, Public Health Medicine

Is it ethical not to disclose results proactively to clients in couple screening?
This was discussed when pilot trials were being planned. A professional ethicist present at the planning stage concluded that as no help can be offered to so called "positive/negative" couples it was quite ethical to construct a system in which that information was not offered to them provided that this was made quite clear from the start. Professor J Chamberlain, director, Institute of
Cancer Research
It has been suggested that screening for cystic fibrosis could be carried out at family planning clinics and by primary care general practitioners for women who are not pregnant. Presumably, those who propose this screening think there is some benefit in knowing heterozygote status. Do you think there is a benefit that you are denying to people in couple screening who are not told their heterozygote status?
Screening for heterozygosity is indeed carried out with the end point being a knowledge of heterozygosity, but I cannot see the advantage if the individual is not planning to have a child.
Couples who are screened during pregnancy have been asked whether they would like to have known about heterozygosity before bonding with their partner and most would not as it might have interfered with the relationship.
Mr Cam Donaldson, deputy director, Health Economics Research Unit
The most ethical way to approach couple screening seems to be to ask patients and see what their preferences are. Were patients actually aware that there was a choice between couple screening and two-step screening?
The answer is a pragmatic one. The two sys-Brock terns do not really mix because the two-step system does require the presence of a :24 hour a day genetic nurse to provide counselling to those individuals who are found to be carriers. For that reason, it is necessary to choose one system of screening or the other.
Professor R Harris, professor, Medical Genetics
If screening is carried out in the antenatal clinic, generally the process would drag on so that termination would be very late, when it becomes more-difficult, more dangerous, and more traumatic. In general practice the process can be completed within the first trimester, which I think is an important point that has been overlooked.
I think it is essential that general practitioners become more educated and more directed towards the rapidly increasing number of ways of screening, many of which will be genetic in the future.
In Scotland all our couples have come for prenatal diagnosis in the first trimester. If our women were booking later and terminations were occurring in the second trimester I would have to agree with you. Dr J Holdsworth, GP trainee, Rugby I would like to make an ethical point. Prenatal screening differs from other forms of screening discussed today because it is not really a form of prevention as it leads eventually to selected termination of the affected fetus. Many would find this unethical. I don't think I can deal with the ethics of abortion. That would get us into deep water indeed and we must simply take our respective positions on that.
